Hyperlipidemia patients with long-term statin treatment are associated with a reduced risk of progression of benign prostatic enlargement

References

• Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289–297.
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999;162:1301–1306.
   PubMed Web of Science ®Google Scholar
• Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol. 1999;162:376–382.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006;97:3–6.
   PubMed Web of Science ®Google Scholar
• Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract. 2008;62:18–26.
   PubMed Web of Science ®Google Scholar
• Sreenivasulu K, Nandeesha H, Dorairajan LN, et al. Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia. Aging Male. 2018;21:138–144.
   PubMed Web of Science ®Google Scholar
• Torrealba N, Rodriguez-Berriguete G, Vera R, et al. Homeostasis: apoptosis and cell cycle in normal and pathological prostate. Aging Male. 2018;1–11. DOI: 10.1080/13685538.2018.1470233
   PubMed Web of Science ®Google Scholar
• Asiedu B, Anang Y, Nyarko A, et al. The role of sex steroid hormones in benign prostatic hyperplasia. Aging Male. 2017;20:17–22.
   PubMed Web of Science ®Google Scholar
• Allen S, Aghajanyan I. Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology. Aging Male. 2017;20:28–32.
   PubMed Web of Science ®Google Scholar
• Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403–415.
   PubMed Web of Science ®Google Scholar
• Calogero AE, Burgio G, Condorelli RA, et al. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2018;1–8. DOI:10.1080/13685538.2018.1434772
   PubMed Web of Science ®Google Scholar
• Arivazhagan J, Nandeesha H, Dorairajan LN, et al. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male. 2017;20:115–118.
   PubMed Web of Science ®Google Scholar
• Besiroglu H, Dursun M, Otunctemur A, et al. The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients: a cross-sectional study. Aging Male. 2017;20:198–204.
   PubMed Web of Science ®Google Scholar
• Almehmadi Y, Yassin DJ, Yassin AA. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. Aging Male. 2015;18:186–194.
   PubMed Web of Science ®Google Scholar
• Teoh JY, Chiu PK, Chan SY, et al. Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer. Aging Male. 2015;18:180–185.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lin J, Johnson-Levonas AO, et al. Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone. Aging Male. 2010;13:40–43.
   PubMed Web of Science ®Google Scholar
• Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51:1202–1216.
   PubMed Web of Science ®Google Scholar
• Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015;115:24–31.
   PubMed Web of Science ®Google Scholar
• Shih HJ, Huang CJ, Lin JA, et al. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia. Prostate. 2018;78:113–120.
   PubMed Web of Science ®Google Scholar
• Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol. 2005;20:541–546.
   PubMed Web of Science ®Google Scholar
• Schooling CM, Au Yeung SL, Freeman G, et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57.
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Jacobsen SJ, Jacobson DJ, et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int. 2011;107:443–450.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zeng X, Dong L, et al. The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome. World J Urol. 2015;33:2071–2077.
   PubMed Web of Science ®Google Scholar
• Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidem Drug Saf. 2011;20:236–242.
   PubMed Web of Science ®Google Scholar
• Li YH, Ueng KC, Jeng JS, et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc. 2017;116:217–248.
   PubMed Web of Science ®Google Scholar
• Qu X, Huang Z, Meng X, et al. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients. Int Urol Nephrol. 2014;46:499–504.
   PubMed Web of Science ®Google Scholar
• Hwang EC, Kim SO, Nam DH, et al. Men with hypertension are more likely to have severe lower urinary tract symptoms and large prostate volume. Low Urin Tract Symptoms. 2015;7:32–36.
   PubMed Web of Science ®Google Scholar
• Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010;5:212–218.
   PubMedGoogle Scholar
• Jung JH, Ahn SV, Song JM, et al. Obesity as a risk factor for prostatic enlargement: a retrospective cohort study in Korea. Int Neurourol J. 2016;20:321–328.
   PubMed Web of Science ®Google Scholar
• Frea B, Annoscia S, Stanta G, et al. Correlation between liver cirrhosis and benign prostatic hyperplasia: a morphological study. Urol Res. 1987;15:311–314.
   PubMedGoogle Scholar
• St Sauver JL, Jacobson DJ, McGree ME, et al. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164:760–768.
   PubMed Web of Science ®Google Scholar
• Wang Z, Xiao X, Ge R, et al. Metformin inhibits the proliferation of benign prostatic epithelial cells. PLoS One. 2017;12:e0173335.
   PubMed Web of Science ®Google Scholar
• Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation. 2011;82:244–252.
   PubMed Web of Science ®Google Scholar
• Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452–454.
   PubMed Web of Science ®Google Scholar
• Besiroglu H, Ozbek E, Dursun M, et al. Visceral adiposity index is associated with benign prostatic enlargement in non-diabetic patients: a cross-sectional study. Aging Male. 2018;21:40–47.
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999;159:1793–1802.
   PubMed Web of Science ®Google Scholar
• Deshpande S, Quek RG, Forbes CA, et al. A systematic review to assess adherence and persistence with statins. Curr Med Res Opin. 2017;33:769–778.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557–563.
   PubMed Web of Science ®Google Scholar
• Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488–494.
   PubMed Web of Science ®Google Scholar
• Kim W, Jung JH, Kang TW, et al. Clinical effects of discontinuing 5-alpha reductase inhibitor in patients with benign prostatic hyperplasia. Korean J Urol. 2014;55:52–56.
   PubMedGoogle Scholar
• Cindolo L, Pirozzi L, Sountoulides P, et al. Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol. 2015;15:96.
   PubMed Web of Science ®Google Scholar
• Li YC, Huang WL. Effects of adherence to statin therapy on health care outcomes and utilizations in Taiwan: a population-based study. BioMed Res Int. 2015;2015:149573.
   PubMed Web of Science ®Google Scholar
• Lopez-Guarnido O, Urquiza-Salvat N, Saiz M, et al. Bioactive compounds of the Mediterranean diet and prostate cancer. Aging Male. 2018;1–10. DOI:10.1080/13685538.2018.1430129
   Web of Science ®Google Scholar
• Pascual-Geler M, Urquiza-Salvat N, Cozar JM, et al. The influence of nutritional factors on prostate cancer incidence and aggressiveness. Aging Male. 2018;21:31–39.
   PubMed Web of Science ®Google Scholar
• Russo GI, Di Mauro M, Regis F, et al. Association between dietary phytoestrogens intakes and prostate cancer risk in Sicily. Aging Male. 2018;21:48–54.
   PubMed Web of Science ®Google Scholar
• Guzelsoy M, Aydos MM, Coban S, et al. Comparison of the effectiveness of IPSS and VPSS without any help in LUTS patients: a prospective study. Aging Male. 2017;1–7. DOI:10.1080/13685538.2017.1414178
   Web of Science ®Google Scholar